News headlines about Codexis (NASDAQ:CDXS) have trended somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Codexis earned a news impact score of 0.06 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.3430122039511 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
A number of research analysts have recently issued reports on CDXS shares. Jefferies Group LLC started coverage on Codexis in a report on Wednesday, May 31st. They issued a “buy” rating and a $8.00 target price on the stock. HC Wainwright set a $8.00 target price on Codexis and gave the company a “buy” rating in a report on Friday, August 11th. Zacks Investment Research raised Codexis from a “hold” rating to a “buy” rating and set a $6.25 target price on the stock in a report on Wednesday, July 19th. BidaskClub raised Codexis from a “hold” rating to a “buy” rating in a report on Sunday, July 16th. Finally, ValuEngine raised Codexis from a “sell” rating to a “hold” rating in a report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. Codexis has an average rating of “Hold” and a consensus price target of $6.80.
Codexis (CDXS) opened at 5.80 on Wednesday. The firm’s market cap is $280.28 million. The company’s 50-day moving average price is $5.38 and its 200-day moving average price is $4.86. Codexis has a one year low of $3.60 and a one year high of $5.80.
Codexis (NASDAQ:CDXS) last announced its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.13). The business had revenue of $10.30 million for the quarter, compared to the consensus estimate of $9.61 million. Codexis had a negative return on equity of 83.39% and a negative net margin of 40.70%. The business’s revenue was down 35.6% on a year-over-year basis. During the same quarter last year, the business posted $0.12 EPS. On average, analysts anticipate that Codexis will post ($0.38) EPS for the current year.
Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.
Receive News & Ratings for Codexis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.